Skip to main content
    T

    Tilray Inc (TLRY)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ

    $3.21
    +0.07 (+2.23%)

    Market Cap: $464.05M

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    34%(11/32)
    Avg Surprise
    -99.40%

    Upcoming Estimates

    Period ending Nov 30, 2026
    EPS Consensus$0.03
    Range$0.03 - $0.03
    1 analysts
    EPS RevisionsNo revisions (7d)No revisions (30d)
    EPS Estimate DriftChange to current
    90d ago$0.00n/a
    60d ago$0.00n/a
    30d ago$0.030.0%
    7d ago$0.030.0%
    Current$0.03
    Revenue Consensus
    $264M
    Range$246M - $272M
    8 analysts
    Period ending Feb 28, 2027
    EPS Consensus$0.03
    Range$0.03 - $0.03
    1 analysts
    EPS RevisionsNo revisions (7d)No revisions (30d)
    EPS Estimate DriftChange to current
    90d ago$0.00n/a
    60d ago$0.00n/a
    30d ago$0.030.0%
    7d ago$0.030.0%
    Current$0.03
    Revenue Consensus
    $267M
    Range$251M - $285M
    8 analysts
    PeriodReportedEst.SurpriseB/MYoY
    May 27EST
    		-$-0.28---
    Feb 27EST
    		-$0.03---
    Nov 26EST
    		-$0.03---
    Aug 26
    Reported Oct 8
    		$-0.32$-0.19-68.42%Miss-106566.7%
    May 26
    Reported Jul 28
    		$-0.43$-0.02-2050.00%Miss-2250.0%
    Feb 26
    Reported Apr 1
    		$0.02N/A-71.43%Miss+102.3%
    Nov 25
    Reported Jan 8
    		$-0.02$-0.02-8.11%Miss+33.3%
    Aug 25
    Reported Oct 9
    		$-0.00N/A+99.26%Beat+99.7%
    May 25
    Reported Jul 28
    		$0.02$-0.02+200.00%Beat+150.0%
    Feb 25
    Reported Apr 8
    		$-0.87$-0.33-163.36%Miss-624.3%
    Nov 24
    Reported Jan 10
    		$-0.03N/A+76.92%Beat+95.0%
    Aug 24
    Reported Oct 10
    		$-0.10N/A+66.67%Beat+89.0%
    May 24
    Reported Jul 29
    		$-0.04$-0.02-100.00%Miss+73.3%
    Feb 24
    Reported Apr 9
    		$-0.12N/A+74.47%Beat+70.0%
    Nov 23
    Reported Jan 9
    		$-0.60$-0.47-27.66%Miss+0.0%
    Aug 23
    Reported Oct 4
    		$-0.91$-0.57-59.65%Miss-13.7%
    May 23
    Reported Jul 26
    		$-0.15$-0.05-200.00%Miss+83.3%
    Feb 23
    Reported Apr 10
    		$-0.40$-0.58+31.03%Beat-154.1%
    Nov 22
    Reported Jan 9
    		$-0.60$-0.54-11.11%Miss-2100.0%
    Aug 22
    Reported Oct 7
    		$-0.80$-0.70-14.29%Miss-14.3%
    May 22
    Reported Jul 28
    		$-0.90$-0.08-1025.00%Miss-433.3%
    Feb 22
    Reported Apr 6
    		$0.74$-0.79+193.67%Beat+1333.3%
    Nov 21
    Reported Jan 10
    		$0.03N/A+103.90%Beat+106.7%
    Aug 21
    Reported Oct 7
    		$-0.70$-0.67-4.48%Miss-3400.0%
    May 21
    Reported Jul 28
    		$0.27$-0.11+345.45%Beat+141.5%
    Feb 21
    Reported May 10
    		$-0.06N/A+80.95%Beat+94.3%
    Nov 20
    Reported Feb 17
    		$-0.45$-0.15-200.00%Miss-32.4%
    Aug 20
    Reported Nov 9
    		$-0.02N/A+90.48%Beat+94.4%
    May 20
    Reported Aug 10
    		$-0.65$-0.27-140.74%Miss-85.7%
    Feb 20
    Reported May 11
    		$-1.05$-0.45-133.33%Miss-425.0%
    Aug 19
    Reported Nov 12
    		$-0.34$-0.30-13.33%Miss-100.0%
    May 19
    Reported Aug 13
    		$-0.36$-0.25-44.00%Miss-300.0%
    Feb 19
    Reported May 14
    		$-0.35$-0.27-29.63%Miss-
    Aug 18
    Reported Nov 13
    		$-0.20$-0.12-66.67%Miss-
    May 18
    Reported Aug 28
    		$-0.17$-0.08-112.50%Miss-
    Feb 18
    Reported Mar 19
    		$-0.09$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio-4.28EV/EBITDAN/A
    Price/FCF-3.38xFCF Yield-29.60%
    Profitability
    Profit Margin-17.10%Operating Margin-6.23%
    ROE-9.38%ROIC-4.70%
    Financial Health
    Debt/Equity0.23xInterest Coverage-3.42x
    Current Ratio1.88xQuick Ratio1.11x
    Trading Statistics
    Beta1.92Avg Volume4.22M
    52-Week High$16.2052-Week Low$3.10

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$3.49
    SMA 20$3.74
    SMA 50$4.18
    SMA 200$5.83
    EMA 10$3.45
    EMA 20$3.67
    EMA 50$4.04
    EMA 200$5.60

    MACD

    Line: -0.26Signal: -0.21Hist: -0.05

    ADX

    ADX: 28.8+DI: 10.4-DI: 34.8

    Aroon & PSAR

    Aroon Up32.0
    Aroon Down100.0
    PSAR$3.72

    Bollinger Bands

    Upper Band$4.40
    Lower Band$3.08
    %B Position3516%(Upper)
    Band Width0.10

    RSI (14-Day)

    Oversold
    28.0

    Momentum Oscillators

    Stoch %K6.5
    Stoch %D5.6
    Williams %R-86.4
    ROC (10d)-10.1%
    Momentum-0.36
    CCI (20d)-139.9
    MFI (14d)15.7

    Volatility Measures

    ATR (14d)$0.18(5.8%)
    StdDev (20d)0.33
    Hist Vol45.2%(High)

    Volume Flow

    VWAP$3.19
    OBV429.6M
    AD Line1737.8B
    CMF (20d)-0.129

    Volume Metrics

    Avg Vol (20d)4.3M
    Vol Ratio0.6x
    VWMA (20d)$3.70

    Pivot Points

    R3$3.44
    R2$3.37
    R1$3.25
    Pivot Point$3.18
    S1$3.06
    S2$2.99
    S3$2.87

    Advanced Oscillators

    TSI-37.44
    Ultimate Osc40.6
    KST-176.22

    Financial Data

    QuarterAug 2026May 2026Feb 2026Nov 2025Aug 2025May 2025Feb 2025Nov 2024Aug 2024May 2024Feb 2024Nov 2023
    Total Revenue$257.15M$281.71M$282.20M$303.85M$287.78M$308.10M$268.34M$295.06M$269.84M$313.23M$255.65M$262.38M
    Cost of Revenue$179.64M$197.38M$207.19M$223.53M$208.84M$215.30M$193.22M$209.43M$189.30M$201.02M$188.60M$198.18M
    Gross Profit$77.51M$84.33M$75.02M$80.32M$78.94M$92.81M$75.12M$85.63M$80.54M$112.21M$67.05M$64.19M
    Operating Expenses$101.56M$88.82M$102.14M$111.45M$76.07M$2.07B$1.17B$144.68M$129.87M$134.73M$178.48M$120.74M
    R&D$89,000$180,000$84,633$108,964$56,319$46,654$122,774$83,922$141,634$536,852$143,880$75,826
    SG&A$57.61M$61.17M$68.73M$71.68M$56.72M$49.82M$56.98M$65.04M$59.54M$65.12M$54.18M$58.68M
    Operating Income$-16,017,000$-4,493,000$-27,122,377$-31,123,317$2.87M$-1,981,423,149$-1,097,644,336$-59,050,316$-49,329,273$-22,517,831$-111,436,541$-56,543,773
    Interest Income$0$0$0$0$0$0$0$0$0$0$0$0
    Interest Expense$6.48M$6.63M$6.78M$7.51M$9.20M$5.44M$12.10M$10.86M$13.28M$12.88M$11.56M$11.68M
    Income Before Tax$-38,306,000$-24,066,000$-31,749,930$-55,827,511$-1,060,450$-1,911,511,441$-1,144,442,896$-116,426,389$-45,546,957$-58,595,960$-146,396,705$-67,110,780
    Income Tax Expense$1.73M$13.86M$2.69M$4.95M$0$-171,718,600$1.74M$2.85M$1.20M$-37,646,446$-3,896,980$-4,576,689
    Net Income$-43,141,000$-49,572,000$-36,272,374$-62,767,708$-442,312$-1,746,516,571$-1,140,261,358$-119,367,855$-52,829,668$-43,257,509$-125,828,629$-66,359,282
    EBITDA$2.62M$14.85M$-8,231,407$-26,027,134$29.51M$-1,843,690,950$-1,083,887,870$-57,938,350$10.64M$15.01M$-90,257,653$-12,709,113
    EBIT$-16,017,000$-4,493,000$-24,972,407$-48,320,140$8.14M$-1,890,455,185$-1,132,341,712$-105,564,085$-32,271,083$-28,228,363$-134,836,070$-55,432,098
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about TLRY

    News

    Two winners can pick a Georgia concert and get a travel gift card from SweetWater.

    Tilray Brands' SweetWater Brewing is offering Georgia music fans a chance to win tickets to AEG venues across the state. The sweepstakes will run until December 31, 2026...

    Stock Titan•10/15/26•Bullish

    Tilray Brands Inc. stock falls Wednesday, underperforms market

    Tilray Brands Inc. (TLRY) shares fell 3.98% to $3.14 on Wednesday, marking its sixth consecutive day of losses. This decline occurred during a challenging trading session for the broader market...

    MarketWatch•10/14/26•Bearish

    Tilray Brands, Inc. (TSX:TLRY) Gains INFARMED Nod for In-House EU-GMP Testing at Portuguese Medical Cannabis Site

    Tilray Medical, a division of Tilray Brands, Inc., has received approval from INFARMED, Portugal's national medicines authority...

    Kalkine Media•10/14/26•Somewhat-Bullish

    Tilray Brands (NASDAQ:TLRY) Stock Price Down 2.7% - Should You Sell?

    Tilray Brands (NASDAQ:TLRY) stock dropped 2.7% to $3.27, trading below its 50-day and 200-day moving averages, amid concerns over declining core cannabis revenue, an adjusted loss, negative free cash flow...

    MarketBeat•10/13/26•Somewhat-Bearish

    Tilray Medical Strengthens Global Medical Cannabis Supply

    Tilray Medical, a division of Tilray Brands, has received approval from INFARMED, Portugal’s National Authority of Medicines and Health Products...

    GlobeNewswire•10/13/26•Bullish

    TLRY Valuation and Fair Value

    P/E
    -4.3x
    Forward P/E
    1000.0x
    P/FCF
    -3.4x
    P/B
    0.3x
    See GNG's fair value

    TLRY Profitability: Margins, ROIC and FCF

    Gross margin
    28.2%
    Operating margin
    -6.2%
    Net margin
    -17.1%
    ROIC
    -4.7%
    ROE
    -9.4%
    FCF margin
    -11.3%
    FCF yield
    -29.6%

    TLRY Competitors

    CompanyTicker
    AngioDynamics IncANGO
    Brainsway LtdBWAY
    Senseonics Holdings, Inc. Common StockSENS
    National Research CorpNRC
    XOMA CorpXOMA
    Cerus CorporationCERS
    Evotec SE ADREVO
    Neurogene IncNGNE

    Sector: Healthcare

    TLRY Analyst Ratings

    Consensus
    Hold
    Analysts
    10
    Strong Buy
    0
    Buy
    3
    Hold
    7
    Sell
    0
    Strong Sell
    0

    TLRY Bull Case vs Bear Case

    Bull case

    • TLRY grew quarterly revenue 22.7% year over year.

    Bear case

    • TLRY has a -17.1% net profit margin.
    • TLRY beat EPS estimates in 37.5% of its last 8 reported quarters.

    TLRY Earnings: Beat Rate and Next Report

    Beat rate
    3 of 8 quarters (37.5%)
    Average surprise
    -248.1%
    EPS estimate (fiscal period ending Nov 30, 2026)
    $0.03
    Estimate revisions (30 days, fiscal period ending Nov 30, 2026)
    0 up, 0 down

    Frequently Asked Questions About TLRY

    Does TLRY pay dividends?

    Tilray Inc (TLRY) does not currently pay a regular dividend.

    What is TLRY's market cap?

    Tilray Inc (TLRY) has a market capitalization of $464.05M with a current stock price of $3.21.

    Related stocks

    Sector: Healthcare

    All stocks starting with T

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In